Stock Groups

Alnylam files patent infringement lawsuits against Pfizer, Moderna -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO : This illustration shows vaccine labels for Vials with Pfizer BioNTech (MOVID-19). It was taken on March 19, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) –Alnylam Pharmaceuticals Inc stated Thursday that it filed separate lawsuits at the Delaware federal courts against Pfizer Inc (NYSE 🙂 Moderna (NASDAQ) Inc., seeking damages in respect of infringement of a patent for the production and sale their mRNA COVID-19 vaccinations.

Alnylam claimed it wanted compensation for the use of its lipid-nanoparticles (LNP), technology which carries and delivers RNA based therapeutics to the body.

Moderna and Pfizer’s vaccines violate Alnylam’s patent by using a lipid that has been formulated into LNPs to protect and deliver vaccines’ DNA, according to the pharmaceutical company.

Moderna was sued by Arbutus Biopharma Corp (NASDAQ:) last month in Delaware Federal Court. Moderna claimed that Moderna’s COVID-19 vaccination violates its patents.

Alnylam indicated that they do not plan to interfere with the manufacture, sale, or distribution vaccines.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages caused by reliance upon the data contained in this site. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]